Sep 28, 2022
Sep 27, 2023
The number of approved drugs for myelodysplastic syndromes (MDS) is limited, and not all agents have been shown to be highly efficacious and to improve survival. However, the oncology community witnessed an explosion of new agents and investigational approaches in 2020 that has persisted until today.
In this virtual symposium hear expert insights regarding the role of cytogenetic abnormalities, new prognostic models, and other patient- and disease-related factors in diagnosis, prognosis, and treatment planning for individuals with MDS. Faculty will also assess the clinical implications of recent and emerging safety and efficacy data for novel agents and combinations and provide strategies for effective communication with patients, including those in special populations and those of diverse backgrounds, to manage symptoms and enhance quality of life.
This virtual Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.
Vice Chair, Department of Malignant Hematology
Senior Member & Professor of Oncologic Sciences
Section Head -- Leukemia & MDS
Vice Chair - Malignant Hematology Department
H Lee Moffitt Cancer Center &Research Institute
Dr. Komrokji is a senior Member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center, and Professor in Medicine & Oncologic Sciences at the College of Medicine, at the University of South Florida in Tampa, Florida.
After earning a medical degree in 1996 from the Jordan University School of Medicine, Dr. Komrokji completed an internship and residency at Case Western University, St. Vincent Program. He then completed a fellowship at Strong Memorial Hospital, University of Rochester, in Hematology/Oncology and Hematopoietic Stem Cell Transplantation.
Dr Komrokji is world renowned expert in myeloid neoplasms where he led several clinical trials and lectured worldwide. His work paved the FDA approval for luspatercept in myelodysplastic syndromes and pending approval for Pacritinib in myelofibrosis.
He has authored or co-authored more than 275 peer-reviewed manuscripts, 20 book chapters, and more than 700 abstracts in Hematologic Malignancies. He served as member on the MDS Panel of the National Comprehensive Cancer Network (NCCN) and currently member of the NIH MDS natural history study steering committee and aplastic anemia and MDS foundation board of directors. He was member of the editorial board for Journal of Clinical Oncology (JCO). He is peer reviewer for several medical journals including Blood Journal, JCO and Leukemia Journal.
Dr. Komrokji’s research interests are in Phase I and II Clinical Trials, and in the outcome research in hematologic malignancies with focus on myeloid neoplasms. His clinical interests are Myelodysplastic syndromes (MDS), Acute Myeloid Leukemias, and Myeloproliferative neoplasms.
Department of Leukemia, Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas, USA
Guillermo Garcia-Manero, MD, is a physician-scientist specializing in state-of-the-art treatments for leukemia. For the last 15 years, Dr. Garcia-Manero efforts has focused on improving the outcomes and quality of life of patients with leukemia and in particular myelodysplastic syndromes. His work centers around the understanding of the pathophysiology of these disorders in an attempt to develop new therapeutic interventions. He currently leads the largest MDS program in the world and directs the MDS/AML Moon Shot ® program at MD Anderson. This work has resulted in over 500 publications in the areas of biology, therapy and prognostication of these disorders, and development of multiple therapeutic clinical trials.
Director, Hematopathology Fellowship Program, Pathology Service
Professor of Pathology, Harvard Medical School
Massachusetts General Hospital
Dr Robert Hasserjian is Professor of Pathology at Harvard Medical School and a Hematopathologist at Massachusetts General Hospital, where he is Director of the Hematopathology Fellowship Program. Dr Hasserjian received his MD from Harvard and trained in Anatomic Pathology and Hematopathology at Brigham and Women's Hospital. His research interests are in the discovery of pathologic and genetic features associated with the biologic behavior of myeloid and lymphoid neoplasms, particularly myelodysplastic syndromes and acute myeloid leukemia. Dr Hasserjian is an author of over 200 peer-reviewed publications, reviews, and chapters and is the editor of the textbook “Diagnosis of Blood and Bone Marrow Disorders” (Springer, 2018). He is currently President of the Society for Hematopathology. He served as a Senior Reviewer and author of multiple chapters of the WHO Classification of Myeloid Neoplasms published in 2017, was a leader of the 2022 International Consensus Classification of Myeloid Neoplasms, and was an expert panel member for the 2022 European LeukemiaNet AML Guidelines. Dr Hasserjian is strongly committed to advancing diagnosis and education in hematopathology and has lectured on the diagnosis of leukemias and other bone marrow disorders at numerous courses and international meetings across the Americas, Europe, and Asia.
This educational activity is directed toward hematologic oncology clinicians, nurses, and pharmacists who provide care for individuals with MDS/sAML.
After completing this CE activity, the participant should be better able to:
Evaluate the role of cytogenetic abnormalities, new prognostic models, and other patient- and disease-related factors in diagnosis, prognosis, and treatment planning
Assess the clinical implications of recent and emerging safety and efficacy data for novel agents and combinations
Communicate effectively with patients, including those in special populations and those of diverse backgrounds, to manage symptoms and enhance quality of life (QoL)
The evolving role of cytogenetic abnormalities, new prognostic models, and other patient-and disease related factors in diagnosis, prognosis, and treatment planning
Clinical implications of recent emerging efficacy and safety data for novel agents and combinations
Case studies: communication effectively with special populations and patients of diverse backgrounds to manage symptoms and improve quality of love; encouraging participation in clinical trials
Accreditation, Support and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and Aplastic Anemia and MDS International Foundation. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting 1.0 AMA PRA Category 1 Credit(s)™ into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and no contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-22-106-H01-P
Type of Activity: Knowledge
Supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., and Aplastic Anemia and MDS International Foundation are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Rami S. Komrokji, MD
Senior Member, Vice Chair, Department of Hematologic Malignancies, H. Moffit Cancer Center & Research Institute
Rami S. Komrokji, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for: Abbvie, CTI BioPharma, Jaxz, Pharma Essentia, Servier, BMS/Celgence, Novartis, and Taiho
Speakers' Bureau for: Abbvie, CTI BioPharma, Jaxz, Pharma Essentia, and Servier
Research Grant for: BMS/Celgence
Independent Contractor for: Geron
Robert Hasserjian, MD
Director, Hematopathology Fellowship Program, Massachusetts General Hospital
Robert Hasserjian, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for: Bluebird, Inc.
Guillermo Garcia-Manero, MD
Chief, Section of MDS, Department of Leukemia, University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and Aplastic Anemia and MDS International Foundation, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
If you have questions regarding your certificate, please contact Mary Vu via email at email@example.com.
About This Activity
Medical Learning Institute, Inc. and Aplastic Anemia and MDS International Foundation are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2022 Medical Learning Institute, Inc | All Rights Reserved